DOCSLIB.ORG

Federal Register/Vol. 86, No. 77/Friday, April 23, 2021/Notices

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 86, No. 77/Friday, April 23, 2021/Notices 21814 Federal Register / Vol. 86, No. 77 / Friday, April 23, 2021 / Notices DEPARTMENT OF JUSTICE Administration; Telephone: (571) 362– compounds, mixtures, or preparations 8201. containing a controlled substance, if he Drug Enforcement Administration SUPPLEMENTARY INFORMATION: finds that such compounds, mixtures, or [Docket No. DEA–372] preparations meet the requirements Posting of Public Comments detailed in 21 U.S.C. 811(g)(3)(B).1 The Exempt Chemical Preparations Under Please note that all comments DEA regulations at 21 CFR 1308.23 and the Controlled Substances Act received are considered part of the 1308.24 further detail the criteria by public record and made available for which the DEA Assistant Administrator AGENCY: Drug Enforcement may exempt a chemical preparation or Administration, Department of Justice. public inspection online at http:// www.regulations.gov and in the DEA’s mixture from certain provisions of the ACTION: Order with opportunity for public docket. Such information CSA. The Assistant Administrator may, comment. includes personal identifying pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which SUMMARY: The applications for exempt information (such as your name, address, etc.) voluntarily submitted by exemptions are granted and modify the chemical preparations received by the scope of exemptions at any time. Drug Enforcement Administration the commenter. The Freedom of (DEA) between July 1, 2018, and Information Act applies to all comments Exempt Chemical Preparation December 31, 2020, as listed below, received. Applications Submitted Between July 1, were accepted for filing and have been If you want to submit personal 2018, and December 31, 2020 approved or denied as indicated. identifying information (such as your The Assistant Administrator received name, address, etc.) as part of your DATES: Interested persons may file applications between July 1, 2018, and comment, but do not want it to be written comments on this order in December 31, 2020, requesting exempt posted online or made available in the accordance with 21 CFR 1308.23(e). chemical preparation status detailed in public docket, you must include the Electronic comments must be 21 CFR 1308.23. Pursuant to the criteria phrase ‘‘PERSONAL IDENTIFYING submitted, and written comments must stated in 21 U.S.C. 811(g)(3)(B) and in INFORMATION’’ in the first paragraph be postmarked, on or before June 22, 21 CFR 1308.23, the Assistant of your comment. You must also place 2021. Commenters should be aware that Administrator has found that each of the all the personal identifying information the electronic Federal Docket compounds, mixtures, and preparations you do not want posted online or made Management System will not accept described in Chart I below is intended available in the public docket in the first comments after 11:59 p.m. Eastern Time for laboratory, industrial, educational, paragraph of your comment and identify on the last day of the comment period. or special research purposes and not for what information you want redacted. general administration to a human being ADDRESSES: To ensure proper handling If you want to submit confidential or animal and either: (1) Contains no of comments, please reference ‘‘Docket business information as part of your narcotic controlled substance and is No. DEA–372’’ on all correspondence, comment, but do not want it to be packaged in such a form or including any attachments. posted online or made available in the concentration that the packaged Electronic comments: DEA encourages public docket, you must include the quantity does not present any that all comments be submitted through phrase ‘‘CONFIDENTIAL BUSINESS significant potential for abuse; or (2) the Federal eRulemaking Portal, which INFORMATION’’ in the first paragraph contains either a narcotic or non- provides the ability to type short of your comment. You must also narcotic controlled substance and one or comments directly into the comment prominently identify confidential more adulterating or denaturing agents field on the web page or to attach a file business information to be redacted in such a manner, combination, for lengthier comments. Please go to within the comment. quantity, proportion, or concentration http://www.regulations.gov and follow Comments containing personal that the preparation or mixture does not the online instructions at that site for identifying information and confidential present any potential for abuse and, if submitting comments. Upon completion business information identified as the preparation or mixture contains a of your submission you will receive a directed above will generally be made narcotic controlled substance, is Comment Tracking Number for your publicly available in redacted form. If a formulated in such a manner that it comment. Please be aware that comment has so much confidential incorporates methods of denaturing or submitted comments are not business information that it cannot be other means so that the preparation or instantaneously available for public effectively redacted, all or part of that mixture is not liable to be abused or view on Regulations.gov. If you have comment may not be made publicly have ill effects, if abused, and so that received a comment tracking number, available. Comments posted to http:// the narcotic substance cannot in your comment has been successfully www.regulations.gov may include any practice be removed. submitted and there is no need to personal identifying information (such Accordingly, pursuant to 21 U.S.C. resubmit the same comment. as name, address, and phone number) 811(g)(3)(B), 21 CFR 1308.23, and 21 Paper comments: Paper comments included in the text of your electronic CFR 1308.24, the Assistant that duplicate the electronic submission submission that is not identified as Administrator has determined that each are not necessary and are discouraged. directed above as confidential. of the chemical preparations or mixtures Should you wish to mail a comment in An electronic copy of this document generally described in Chart I below and lieu of an electronic comment, it should is available at http:// specifically described in the application be sent via regular or express mail to: www.regulations.gov for easy reference. materials received by DEA is exempt, to Drug Enforcement Administration, the extent described in 21 CFR 1308.24, Attention: DEA Federal Register Legal Authority Representative/DRW, 8701 Morrissette Section 201 of the Controlled 1 This authority has been delegated from the Drive, Springfield, Virginia 22152. Substances Act (CSA) (21 U.S.C. 811) Attorney General to the Administrator of the DEA FOR FURTHER INFORMATION CONTACT: by 28 CFR 0.100, and subsequently redelegated to authorizes the Attorney General, by the Deputy Assistant Administrator pursuant to 28 Terrence L. Boos, Ph.D., Diversion regulation, to exempt from certain CFR 0.104 and Section 7 of the appendix to subpart Control Division, Drug Enforcement provisions of the CSA certain R of part 0. VerDate Sep<11>2014 18:41 Apr 22, 2021 Jkt 253001 PO 00000 Frm 00002 Fmt 4701 Sfmt 4703 E:\FR\FM\23APN2.SGM 23APN2 khammond on DSKJM1Z7X2PROD with NOTICES2 Federal Register / Vol. 86, No. 77 / Friday, April 23, 2021 / Notices 21815 from application of sections 302, 303, mixture after the date of application July 1, 2018, and December 31, 2020, 305, 306, 307, 308, 309, 1002, 1003, and requires a new application. The and not otherwise referenced in this 1004 (21 U.S.C. 822–823, 825–829, and requirements set forth in 21 CFR order, may remain under consideration 952–954) of the CSA, and 21 CFR 1308.24(b)–(e) apply to the exempted until DEA receives additional 1301.74, as of the date that was materials. In accordance with 21 CFR information required, pursuant to 21 provided in the approval letters to the 1308.24(g), DEA may prescribe CFR 1308.23(d), as detailed in separate individual requesters. requirements other than those set forth correspondence to individual in 21 CFR 1308.24(b)–(e) on a case-by- requesters. DEA’s order on such Scope of Approval case basis for materials exempted in requests will be communicated to the The exemptions are applicable only to bulk quantities. Accordingly, in order to public in a future Federal Register the precise preparation or mixture limit opportunity for diversion from the publication. described in the application submitted larger bulk quantities, DEA has DEA also notes that these exemptions to DEA in the form(s) listed in this order determined that each of the exempted are limited to exemption from only and only for those above mentioned bulk products listed in this order may those sections of the CSA and the CFR sections of the CSA and the CFR. In only be used in-house by the that are specifically identified in 21 CFR accordance with 21 CFR 1308.24(h), any manufacturer, and may not be 1308.24(a). All other requirements of the change in the quantitative or qualitative distributed for any purpose, or CSA and the CFR apply, including composition of the preparation or transported to other facilities. registration as an importer as required mixture, or change in the trade name or Additional exempt chemical by 21 U.S.C. 957. other designation of the preparation or preparation requests received between BILLING CODE 4410–09–P VerDate Sep<11>2014 18:41 Apr 22, 2021 Jkt 253001 PO 00000 Frm 00003 Fmt 4701 Sfmt 4703 E:\FR\FM\23APN2.SGM 23APN2 khammond on DSKJM1Z7X2PROD with NOTICES2 21816 Federal Register / Vol. 86, No. 77 / Friday, April 23, 2021 / Notices Chart I Glass or plastic bottle Aalto Scientific, Ltd. Abbott FLQ TDM Base 4/22/2020 or flask: 1-100 mL Glass or plastic bottle Aalto Scientific, Ltd. Abbott FLQ TDM Base 4/22/2020 or flask: 100-500 mL Glass or plastic bottle Aalto Scientific, Ltd.
Load more

Recommended publications
  • Analysis of Drugs Manual September 2019
    Drug Enforcement Administration Office of Forensic Sciences Analysis of Drugs Manual September 2019 Date Posted: 10/23/2019 Analysis of Drugs Manual Revision: 4 Issue Date: September 5, 2019 Effective Date: September 9, 2019 Approved By: Nelson A. Santos Table of Contents CHAPTER 1 – QUALITY ASSURANCE ......................................................................... 3 CHAPTER 2 – EVIDENCE ANALYSIS ......................................................................... 93 CHAPTER 3 – FIELD ASSISTANCE .......................................................................... 165 CHAPTER 4 – FINGERPRINT AND SPECIAL PROGRAMS ..................................... 179 Appendix 1A – Definitions ........................................................................................... 202 Appendix 1B – Acronyms and Abbreviations .............................................................. 211 Appendix 1C – Instrument Maintenance Schedule ..................................................... 218 Appendix 1D – Color Test Reagent Preparation and Procedures ............................... 224 Appendix 1E – Crystal and Precipitate Test Reagent Preparation and Procedures .... 241 Appendix 1F – Thin Layer Chromatography................................................................ 250 Appendix 1G – Qualitative Method Modifications ........................................................ 254 Appendix 1H – Analytical Supplies and Services ........................................................ 256 Appendix 2A – Random Sampling Procedures
    [Show full text]
  • Anabolic Steroid Use Misuse and Addiction
    Anabolic Steroid Use, Misuse And Addiction JASSIN M. JOURIA Dr. Jassin M. Jouria is a medical doctor, professor of academic medicine, and medical author. He graduated from Ross University School of Medicine and has completed his clinical clerkship training in various teaching hospitals throughout New York, including King’s County Hospital Center and Brookdale Medical Center, among others. Dr. Jouria has passed all USMLE medical board exams, and has served as a test prep tutor and instructor for Kaplan. He has developed several medical courses and curricula for a variety of educational institutions. Dr. Jouria has also served on multiple levels in the academic field including faculty member and Department Chair. Dr. Jouria continues to serve as a Subject Matter Expert for several continuing education organizations covering multiple basic medical sciences. He has also developed several continuing medical education courses covering various topics in clinical medicine. Recently, Dr. Jouria has been contracted by the University of Miami/Jackson Memorial Hospital’s Department of Surgery to develop an e-module training series for trauma patient management. Dr. Jouria is currently authoring an academic textbook on Human Anatomy & Physiology. ABSTRACT The synthetic versions of the male hormone testosterone, also known as anabolic steroids, can play an important role in the treatment of health conditions when used as prescribed by a medical clinician. However, misuse of anabolic steroids occurs when these substances are used solely to improve physical appearance or performance. Because there are some potentially serious physical effects of anabolic steroid use, it is important that anabolic steroids are only used as prescribed and always under a medical clinician’s guidance.
    [Show full text]
  • Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
    cells Article Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma Tamara T. Lah 1,2,3,*, Metka Novak 1, Milagros A. Pena Almidon 4, Oliviero Marinelli 4 , Barbara Žvar Baškoviˇc 1, Bernarda Majc 1,3, Mateja Mlinar 1, Roman Bošnjak 5, Barbara Breznik 1 , Roby Zomer 6 and Massimo Nabissi 4 1 Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, 1000 Ljubljana, Slovenia; [email protected] (M.N.); [email protected] (B.Ž.B.); [email protected] (B.M.); [email protected] (M.M.); [email protected] (B.B.) 2 Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia 3 Jožef Stefan International Postgraduate School, 1000 Ljubljana, Slovenia 4 School of Pharmacy, Experimental Medicine Section, University of Camerino, 62032 Camerino, Italy; [email protected] (M.A.P.A.); [email protected] (O.M.); [email protected] (M.N.) 5 Department of Neurosurgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; [email protected] 6 MGC Pharmaceuticals d.o.o., 1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-651-629 Simple Summary: Among primary brain tumours, glioblastoma is the most aggressive. As early relapses are unavoidable despite standard-of-care treatment, the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone or in combination have been suggested as a combined treatment strategy for glioblastomas. However, the known psychoactive effects of THC hamper its medical applications in these patients with potential cognitive impairment due to the progression of the Citation: Lah, T.T.; Novak, M.; Pena Almidon, M.A.; Marinelli, O.; disease.
    [Show full text]
  • Anabolic Androgenic Steroid Use Prevalence, Knowledge, and Practice Among Male Athletes in Eastern Province of Saudi Arabia
    Electronic Journal of General Medicine 2020, 17(2), em187 e-ISSN: 2516-3507 https://www.ejgm.co.uk/ Original Article OPEN ACCESS Anabolic Androgenic Steroid Use Prevalence, Knowledge, and Practice among Male Athletes in Eastern Province of Saudi Arabia Huda Hassan Aldarweesh 1, Alyaa Hassan Alhajjaj 1* 1 Qatif Central Hospital, SAUDI ARABIA *Corresponding Author: [email protected] Citation: Aldarweesh HH, AlHajjaj AH. Anabolic Androgenic Steroid Use Prevalence, Knowledge, and Practice among Male Athletes in Eastern Province of Saudi Arabia. Electron J Gen Med. 2020;17(2):em187. https://doi.org/10.29333/ejgm/7617 ARTICLE INFO ABSTRACT Received: 25 Oct. 2019 Background: Anabolic androgenic steroids (AAS) are synthetic testosterone like hormones. AAS usage by athletes Accepted: 30 Dec. 2019 has increased dramatically over the past decade. Material and Methods: This study was designed to examine the prevalence, attitude and awareness of AAS abuse among athletes n the Eastern province of Saud Arabia. This was a cross-sectional survey that was conducted among male athletes attending twenty fitness centres in the Eastern Province. It was done during the period from April to August, 2018. Results: A total of 573 questionnaires were distributed but only 503 participants were included n the final analysis. The frequency of AAS use was 17.69%. The man reason for AAS use was muscle building (68.54%). The man source of AAS was the coaches. 56.18% of the users recognize the harmful effects of AAS. The most commonly used oral AAS form was oxandrolone (61.80%). The most commonly used substance for post cycle therapy was Tamoxifen citrate n 67.42% of the users.
    [Show full text]
  • Metabolism of Anabolic Steroids in Man: Synthesis and Use of Reference Substances for Identification of Anabolic Steroid Metabolites
    Anaiytzca Chumca Acta, 275 (1993) 23-48 23 Elsevler hence Publishers B V , Amsterdam Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites Will1 Schanxer and Manfred Domke LkutscheS’rthochschuk Koln, Inrhtut f?u Bwchemre, Carl-L&m-Weg 4 5ooO Cologne 41 (Germuny) (Recewed 20th May 1992) AhStl-& The use of anabohc steroids was banned by the International Olympic Comnuttee for the first tune at the Olympic Games m Montreal m 1976 Since that tie the nususe of anabohc steroxls by athletes has been controlled by analysis of urme extracts by gas chromatography-mass spectrometry @C-MS) The excreted steroids or their metabohtes, or both, are isolated from urme by XAD-2 adsorption, enzymatx hydrolyss of coqlugated excreted metabobtes anth /?-glucuromdase from Es&en&u co& bqmd-bqmd extractlon mth diethyl ether, and courted mto tnmethylsdyl (‘INiS) derwatwes The confirmation of an anabobc stenxd nususe ts based on comparison of the electron nnpact lomzation (EI) mass spectrum and GC retention tie of the isolated steroid and/or its metabohte with the El mass spectrum and GC retention time of authentic reference substances For this purpose excretion studies with the most common anabobc steroids were performed and the mam excreted metabobtes were synthesued for bolasterone, boldenone, 4-chiorodehydromethyltestosterone, clostebol, drostanolone, tluoxymesterone, forme- bolone, me&a&one, mesterolone, metandlenone, methandnol, metenolone, methyltestosterone, nandrolone, norethandrolone,
    [Show full text]
  • A Dissertation Entitled Uncovering Cannabinoid Signaling in C. Elegans
    A Dissertation Entitled Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medicinal Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology ________________________________________ Dr. Richard Komuniecki, Committee Chair _______________________________________ Dr. Bruce Bamber, Committee Member ________________________________________ Dr. Patricia Komuniecki, Committee Member ________________________________________ Dr. Robert Steven, Committee Member ________________________________________ Dr. Ajith Karunarathne, Committee Member ________________________________________ Dr. Jianyang Du, Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo August 2018 Copyright 2018, Mitchell Duane Oakes This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medical Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology The University of Toledo August 2018 Cannabis or marijuana, a popular recreational drug, alters sensory perception and exerts a range of medicinal benefits. The present study demonstrates that C. elegans exposed to
    [Show full text]
  • Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol Acetate Is Also Used in the Treatment of Ano- 16
    Megestrol Acetate/Melengestrol Acetate 2115 Adverse Effects and Precautions Megestrol acetate is also used in the treatment of ano- 16. Mwamburi DM, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar As for progestogens in general (see Progesterone, rexia and cachexia (see below) in patients with cancer results in 2 months. Clin Infect Dis 2004; 38: 895–902. p.2125). The weight gain that may occur with meges- or AIDS. The usual dose is 400 to 800 mg daily, as tab- 17. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associ- ated weight loss in men: a randomized, double-blind, placebo- trol acetate appears to be associated with an increased lets or oral suspension. A suspension of megestrol ace- controlled study. J Acquir Immune Defic Syndr 2006; 41: appetite and food intake rather than with fluid reten- tate that has an increased bioavailability is also availa- 304–14. tion. Megestrol acetate may have glucocorticoid ef- ble (Megace ES; Par Pharmaceutical, USA) and is Hot flushes. Megestrol has been used to treat hot flushes in fects when given long term. given in a dose of 625 mg in 5 mL daily for anorexia, women with breast cancer (to avoid the potentially tumour-stim- cachexia, or unexplained significant weight loss in pa- ulating effects of an oestrogen—see Malignant Neoplasms, un- Effects on carbohydrate metabolism. Megestrol therapy der Precautions of HRT, p.2075), as well as in men with hot 1-3 4 tients with AIDS. has been associated with hyperglycaemia or diabetes mellitus flushes after orchidectomy or anti-androgen therapy for prostate in AIDS patients being treated for cachexia.
    [Show full text]
  • Acupuncture and Traditional Chinese Medicine in the Treatment of Parkinson’S Disease
    Schulz Capstone Acupuncture and Traditional Chinese Medicine In the Treatment of Parkinson’s Disease By Mary M. Schulz Presented in partial fulfillment for the Doctor of Acupuncture and Oriental Medicine Degree Capstone Advisors: Eric Tamrazian, M.D., Lawrence J. Ryan, Ph.D. Yo San University April 2014 Schulz Capstone Approvals Signatures Page This Capstone Project has been reviewed and approved by: _________________________________________ __5/4/2015__________ Eric Tamrazian, M.D., Capstone Project Advisor Date _________________________________________ _5/4/2015____________ Lawrence Ryan, Ph.D., Capstone Project Advisor Date _________________________________________ __5/4/2015___________ Don Lee, L.Ac., Specialty Chair Date _________________________________________ __5/4/2015____________ Andrea Murchison, DAOM, L.Ac., Program Director Date 2 Schulz Capstone ABSTRACT Research has shown that arresting progress of disease by early intervention is paramount to preventing its progression. Recent studies reveal early signs and symptoms of Parkinson’s Disease (PD) to be anosmia (loss of smell), constipation and REM Sleep Disorder and are confirmed to develop up to ten years prior to the more well known, and classical diagnosed, motor symptoms of resting tremor, bradykinesia, and rigidity. Motor symptoms in PD appear as a result of the progressive loss of dopamine in the basal ganglia, particularly within the substantia nigra, pars compacta region. By the time PD motor symptoms develop and are diagnosed, an estimated 80% of striatal nerve terminals and 60% of dopaminergic neurons have already been lost. Modern biomedical intervention for motor symptoms primarily focuses on the use of the pharmaceutical combination of carbidopa/levodopa (L-Dopa therapy). It is well known L- Dopa therapy has a waning period after 3 to 5 years of use, with up to 50% of patients developing dyskinesias as a result of this treatment.
    [Show full text]
  • Microgram Journal, Vol 2, Number 1
    Washington, D. C. Office of Science and Education Vol.II,No.1 Division of Laboratory Operations January 1969 INDEXISSUE CORRECTION 11 "Structure Elucidation of 'LBJ' , by Sander W. Bellman, John W. Turczan, James Heagy and Ted M. Hopes, Micro­ Gram .!., 3, 6-13 (Dec. 1968) Page 7, third and fourth sentences under Discussion: Change to read: "The melting point of the acid moiety found in step (g) was 148-150°c., compared to the litera­ ture, v~lue of 151°c for the melting point of benzilic acid (2); thus the benzilic acid melting point gives support to the proposed structure for 'LBJ'. Spectral evidence also supports the proposed structure". MICRO-GRAMREVISION Please re-number the pages of your copies of Micro-Gram, Volume I. Re-number pages bearing printing only. Vol­ ume I will then be numbered from page 1, the front page of issue No. 1, through page 189 the last page of issue No. 12. To help with this task, pages contained within each issue are as follows: Issue Number Page Through 1 1 8 2 9 29 3 30 32 4 33 66 5 67 79 6 80 97 7 98 120 8 121 128 9 129 136 10 137 157 11 158 170 12 171 189 CAUTION: Use of this publication should be restricted to forensic analysts or others having a legitimate need for this material. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -2- CANNABIS ,·,-...__/' Attached is a copy of 11A Short Rapid Method for the Identification of Cannabis." The method was developed by Mro H.D.
    [Show full text]
  • Tuning Drug Release from Polyoxazoline-Drug Conjugates T ⁎ J
    European Polymer Journal 120 (2019) 109241 Contents lists available at ScienceDirect European Polymer Journal journal homepage: www.elsevier.com/locate/europolj Tuning drug release from polyoxazoline-drug conjugates T ⁎ J. Milton Harrisa, ,1, Michael D. Bentleya, Randall W. Moreaditha, Tacey X. Viegasa,1, Zhihao Fanga, Kunsang Yoona, Rebecca Weimera, Bekir Dizmanb, Lars Nordstiernac a Serina Therapeutics, Inc., 601 Genome Way, Suite 2001, Huntsville, AL 35806, USA2 b Sabanci University, Faculty of Engineering and Natural Sciences, Tuzla, 34956 İstanbul, Turkey2 c Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Göteborg, Sweden ARTICLE INFO ABSTRACT Keywords: Poly(2-oxazoline)-drug conjugates with drugs attached via releasable linkages are being developed for drug Poly(2-oxazoline) or POZ delivery. Such conjugates with pendent ester linkages that covalently bind drugs to the polymer backbone ex- Poly(2-ethyl-2-oxazoline) or PEOZ hibit significantly slower hydrolytic release rates in plasma than the corresponding PEG- and dextran-drug Pendent drugs conjugates. The slow drug release rates in-vitro of these POZ-drug conjugates contribute to extended in-vivo Degradable ester linkages pharmacokinetic profiles. In some instances, the release kinetics may be relatively sustained and ideal foronce-a- Pharmacokinetics week subcutaneous injection, whereas the native drug by itself may only have an in-vivo half-life of a few hours. Drug delivery Phenolic drugs The origin of this unusual kinetic and pharmacokinetic behavior is proposed here to involve folding of the POZ conjugate such that the relatively hydrophobic drug forms a central core, and the relatively hydrophilic polymer wraps around the core and slows enzymatic attack on the drug-polymer chemical linkage.
    [Show full text]
  • MMC International BV
    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]
  • M.M.C. International
    M.M.C. International Clenbuterol/ Oxymetholone Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Ephedrine Test Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black the sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]